Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6006 mRNA Vaccine Phase 1 in Healthy Adults Aged 60+
NCT05354063Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SYS6006 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: adverse events, including solicited and unsolicited events and adverse events associated with the study intervention. Status: unknown.
02
Drugs
SYS6006
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05354063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354063.